60 Degrees Pharmaceuticals, Inc.
SXTPHealthcareNASDAQBiotechnology · Last scanned Oct 24, 2026
Scan Results
Daily timeframe60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the. With a market capitalization of $3.1M, it sits in micro-cap territory. It offers Arakoda for malaria prevention treatment.
Market Cap
$3.1M
Beta
2.40
P/E (TTM)
—
P/E (Fwd)
-0.24
EPS (TTM)
$-5.34
EPS (Fwd)
$-3.58
ROE
-332.9%
ROA
-127.1%
Cash
$1.0M
Total Debt
$151,179
Free CF
-$6.1M
52W Change
-85.2%
Annual Financials
Cash vs Debt
Where SXTP stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, SXTP finished 41.13% below its 150-day moving average ($1.41) and 54.64% below its 200-day moving average ($1.83). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is SXTP overbought or oversold?
At the October 20, 2026 close, SXTP's RSI(14) was 28.9, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $1.0M in cash and $151K in debt, SXTP maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow is running at -$6.1M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -332.9%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $223K (2022) to $1.0M (2025), reflecting a 350% increase over the period.
60 Degrees Pharmaceuticals, Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. With cash comfortably exceeding debt, SXTP has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing SXTP's risk profile alongside its fundamentals and technical indicators provides a more complete picture.